Elevated levels of eEF1A2 protein expression in triple negative breast cancer relate with poor prognosis by Giudici, F. et al.
RESEARCH ARTICLE
Elevated levels of eEF1A2 protein expression
in triple negative breast cancer relate with
poor prognosis
Fabiola Giudici1, Elisabetta Petracci2, Oriana Nanni2, Cristina Bottin3,
Maurizio Pinamonti3, Fabrizio Zanconati3, Bruna ScaggianteID4*
1 Biostatistics Unit, Department of Medical, Surgical and Health Sciences, University of Trieste, Cattinara
Academic Hospital, Trieste, Italy, 2 Unit of Biostatistics and Clinical Trials, Istituto Scientifico Romagnolo per
lo Studio e la Cura dei Tumori, Meldola, Italy, 3 Department of Medical, Surgical and Health Sciences,
University of Trieste, Cattinara Academic Hospital, Trieste, Italy, 4 Department of Life Sciences, University of
Trieste, Trieste, Italy
* bscaggiante@units.it
Abstract
Eukaryotic elongation factor 1 alpha 2 (eEF1A2) is a translation factor selectively expressed
by heart, skeletal muscle, nervous system and some specialized cells. Its ectopic expres-
sion relates with tumorigenesis in several types of human cancer. No data are available
about the role of eEF1A2 in Triple Negative Breast Cancers (TNBC). This study investigated
the relation between eEF1A2 protein levels and the prognosis of TNBC. A total of 84 TNBC
diagnosed in the period 2002–2011 were included in the study. eEF1A2 protein level was
measured in formalin-fixed paraffin-embedded tissues by immunohistochemistry in a semi-
quantitative manner (sum of the percentage of positive cells x staining intensity) on a scale
from 0 to 300. Cox regression assessed the association between eEF1A2 levels and dis-
ease-free survival (DFS) and breast cancer-specific survival (BCSS). Elevated values of
eEF1A2 were associated with older age at diagnosis (p = 0.003), and androgen receptors
positivity (p = 0.002). At univariate Cox analysis, eEF1A2 levels were not significantly asso-
ciated with DFS and BCSS (p = 0.11 and p = 0.08, respectively) whereas adjusting for stage
of disease, elevated levels of eEF1A2 protein resulted associated with poor prognosis
(HR = 1.05, 95% CI: 1.01–1.11, p = 0.04 and HR = 1.07, 95% CI: 1.01–1.14, p = 0.03 for
DFS and BCSS, respectively). This trend was confirmed analyzing negative versus positive
samples by using categorized scores. Our data showed a negative prognostic role of
eEF1A2 protein in TNBC, sustaining further investigations to confirm this result by wider and
independent cohorts of patients.
Introduction
Breast cancer is the most common cancer in women, and the second most frequent cause of
cancer-related deaths in women worldwide [1,2]. Prognostic factors include histological fea-
tures (histological type, histological grade, lymphovascular invasion), tumor size, lymph node
status, steroid hormone receptors status and age [3–5]. Molecular stratification based on gene
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expression profiling revealed that breast cancers could be classified in the so-called intrinsic
subtypes-Luminal A, Luminal B, HER2-enriched, basal-like, and normal-like- [6], which cor-
relate with the efficacy of chemotherapy and life expectancy [7].The St. Gallen International
Expert Consensus proposed a method for classifying breast cancer into 4 subtypes using
immunostaining: Luminal A, Luminal B, Human Epidermal growth factor Receptor 2 (HER2)
positive and triple negative- type breast cancer (TNBC) [8]. Approximately 15–20% of all
breast cancers are triple-negative breast cancer (TNBC) due to the lack of expression of three
proteins: estrogen receptor (ER), progesterone receptor (PR), and HER2 [9].
TNBC tends to be more aggressive than other breast cancer subtypes, with a higher preva-
lence in African-Americans and more frequently affecting younger patients (average age<50
years) [1,2,10]. The clinical-pathological parameters consist of large tumors size, multiple apo-
ptotic cells, high proliferative index, poor differentiation, central necrosis. The major histologi-
cal type of TNBC is not otherwise specified (NOS) ductal and less commonly medullary [11].
TNBC is highly malignant, prone to metastasis and relapse, and, therefore, it has a poorer
prognosis and a greater risk of mortality than other subtypes [12].
Currently, breast cancer’s therapeutic options are highly dependent on targeting ER, PR, or
HER2. Unfortunately, TNBC cannot benefit from endocrine or targeted therapies [13,14].
Although TNBC patients can initially respond to the combination of chemotherapy, treatment
failure and disease recurrence continue to be a clinical challenge [15]. The Food and Drug
Administration (FDA)-approved biomarkers can be surrogate, prognostic, predictive, or phar-
macodynamics [16] and some of them provided a cornerstone of modern cancer therapies, as
the case of prognostic and predictive biomarkers p53 [17] and Ki-67 [18] that gained clinical
utility in breast cancer too [19]. Unfortunately, these FDA biomarkers have not demonstrated
significant clinical utility in the management of TNBC [20]. The research on cancer-related
molecules in TNBC has grown considerably in recent years and some targeted agents are cur-
rently studying as candidates for therapy [21]. However, the possibility to anticipate the
response to therapies and the risk of recurrence in TNBC by using tissue or blood biomarkers
remains an important goal which has not been reached yet.
Among cancer-related biomarkers, eukaryotic Elongation Factor 1 Alpha (eEF1A) proteins
have gained interest as potential predictors of cancer onset and progression in many human
solid and hematopoietic cancers. Two main isoforms of eEF1A, namely eEF1A1 and eEF1A2,
were identified and they play an important role in the elongation of nascent polypeptides dur-
ing the protein synthesis by binding the aminoacylated tRNAs and carrying them to ribo-
somes. In particular, the eEF1A2 was first recognized as a tissue-specific variant of eEF1A1
(formerly known as EF-1α) in the early 1990s [22,23]. The isoforms are encoded by separate
loci, EEF1A1 in 6q13 and EEF1A2 in 20q11, but the resulting proteins are highly homologous
sharing 92% identity and 98% similarity. It is worth noting that their expression pattern is
markedly different: eEF1A1 is expressed ubiquitously, whereas eEF1A2 expression after birth
is limited to the heart, skeletal muscle, brain and to some specialized cells [23–25].
The eEF1A proteins have many translation-independent roles, as they are involved in vari-
ous important cellular mechanisms: embryogenesis, senescence, cell proliferation, apoptosis,
cytoskeletal organization and protein degradation. eEF1A1 is a major cytoskeletal remodeling
factor by binding actin, it displays chaperone-like activity and takes part in proteasome-medi-
ated proteins degradation; it is also involved in the control of cell cycle, growth and death and
in the modulation of cell signaling. The eEF1A2 participates in the activation of kinases signal-
ing pathways and in modulation of cytoskeletal organization by filipodia. Thus, eEF1A1 and
eEF1A2 have similar canonical translation elongation functions, but they differ in the non-
canonical functions, such as cytoskeleton modification [26,27] and protein degradation [28],
as well as cell proliferation, migration and phosphatidylinositol signaling [29].
A pilot study to evaluate the prognostic significance of eEF1A2 expression in TBNC tissues
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The role of eEF1A1 isoform in tumor onset and progression is less clear because of its ubiq-
uitous expression; it is one of the most abundant protein in the cells. On the contrary, eEF1A2
was widely recognized to be an oncogene in many tumors.
For many human tumors, eEF1A2 is a putative oncogene because of its ectopic expression,
that relates with tumor onset as firstly demonstrated in 2002, when Anand et al. found expres-
sion of eEF1A2 in 30% of ovarian tumors, but not in normal ovary cells [29]. Interestingly, it
was known that a high proportion of ovarian and breast tumors had amplification of the
20q11 region, in which eEF1A2 maps, [30,31] and Anand et al., demonstrated that 14/53 of
ovarian tumors brought amplifications of the region surrounding EEF1A2 gene [29]. In gen-
eral, cancer development and aggressiveness of ovarian, breast, lung, gastric, hepatic and pan-
creatic cancers were associated with overexpression of eEF1A2 [32,33]. The eEF1A2 protein
resulted to sustain both prostate cancer and hepatocarcinoma [34–37].
In breast cancers, the overexpression of eEF1A2 is related with a positive prognosis in two
studies [38,39]. Moreover, in an analysis based on a transcription genes database, it resulted to
be a negative factor for Distant Metastasis Free Survival in Luminal A while a positive factor
for Post Progression Survival in HER2+ cancer subtypes [40]. However, the levels of eEF1A2
protein has not been dissected in the TNBC yet.
In this study, we evaluated, by an immunohistochemically fine-timing technique, the
expression of eEF1A2 protein in formalin-fixed paraffin-embedded tissues of a cohort of
TNBC patients to explore the potential significance of eEF1A2 as prognostic biomarker. For
this purpose, we investigated the relationship between eEF1A2 levels and clinical-pathological
status, clinical outcomes and some molecular information such as expression of p53, Ki-67,
and androgen receptors (AR).
Materials and methods
Ethics statement
This study was a retrospective study. All the specimens were retrieved from the archive of
pathological anatomy of the Azienda Sanitaria Universitaria Integrata di Trieste (ASUITS)-
Cattinara Hospital. The study was approved by the Independent Ethics Committee (Comitato
Etico Unico Regionale–CEUR) of Friuli Venezia Giulia and was conducted in accordance with
the approved guidelines and regulations. All patients signed the informed consent and
patients’ data were anonymized by assigning a numbered code. The Ethics Committee also
remitted the informed consent.
Study population
This retrospective single center cohort study was conducted on routinely recorded data
extracted from the database of the Breast Unit of Trieste, Italy. The cohort included women
with invasive TNBC surgically treated in ASUITS between January 2002 and December 2011.
TNBC was defined as tumor with negative IHC for the estrogen (<1%), progesterone (<1%)
and low or absent HER2-amplification (IHC zero or 1+ or negative in situ hybridization).
Data on patients’ follow-up and causes of death were retrieved from the Computerized Medi-
cal Records of ASUITS.
Patients who had a previous history of breast cancer or distant metastasis at diagnosis were
excluded. Women who underwent neoadjuvant chemotherapy or with no adjuvant chemo-
therapy treatment were also excluded to guarantee a study population as homogeneous as pos-
sible. Furthermore, women with unknown outcomes or with insufficient evaluable sample
tissues were excluded.
A pilot study to evaluate the prognostic significance of eEF1A2 expression in TBNC tissues
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Patient and tumor characteristics examined, have included age, type of surgery, histology,
tumor size (pT), lymph node status (pN), stage, tumor grade, familiarity, adjuvant systemic
treatment, and adjuvant radiotherapy.
Molecular information comprised the proliferation index Ki-67 (cut-off of positivity 20%
[8], p53, androgen receptors (cut-off of positivity 10%) and eEF1A2 expression (obtained
using IHC technique).
The main study end-points were Disease-Free Survival (DFS) and Breast Cancer-Specific
Survival (BCSS). DFS was defined as the time from the date of surgery to the date of the first
event, including local/regional disease recurrence, distant metastasis, invasive or in situ contra-
lateral breast cancer, and second primary invasive cancer (non-breast cancer) according to
recent guidelines [41]. BCSS was defined as the time from date of surgery to death from breast
cancer. Deaths for other causes or patients lost to follow-up were censored. Last follow-up
update on May 30, 2017.
Immunohistochemistry procedure for eEF1A2 expression
Immunohistochemistry (IHC) was performed on formalin-fixed, paraffin-embedded tissue
sections 3μm thin. Slides were placed for 20 minutes in 10mM sodium citrate buffer, pH 6.5
heat at 97˚C in order to unmask antigens. To reduce nonspecific background staining due to
endogenous peroxidase, specimens were incubated in UltraVision Hydrogen Peroxide Block
(Thermo Scientific) for 10 minutes and after they were washed in Tris Buffer, for 5 minutes in
Ultra Vision Protein Block (Thermo Scientific) to block nonspecific background staining. Sec-
tions were incubated for 60 minutes at room temperature with EF-1 alfa 2 (D-15 santa cruz-
68481) to detect eEF1A2:sc-68481 mixed with EF-1 alfa1 (CBP-KK1): sc-21758 used at 1:300
dilution and after washed in Tris Buffer, for 30 minutes at room temperature with goat anti-
rabbit IgG,F(ab’)2 –HRP: santa cruz-3837 used at 1:300 dilution. Finally, sections were incu-
bated for 10 minutes with 3,3’ Diaminobenzidine chromogen (DAB Quanto–Thermo Scien-
tific) and hematoxylin to nuclear counter stain.
As positive controls, we used staining intensity of eEF1A2 in normal breast parenchyma
(external positive control) and staining intensity of eEF1A2 in normal breast parenchyma, if
present in tumor tissue section (internal control).
Interpretation of immunohistochemical staining
The intensity of cytoplasmic staining for eEF1A2 was scored as 0 to 3+: 0, complete absence of
staining in the cytoplasm and membrane of cancer cells or staining considerably weaker than
normal breast acini; 1+, weak cytoplasmic staining or equal to normal breast acini; 2+, moder-
ate cytoplasmic staining or slightly stronger than normal breast acini; 3+, strong cytoplasmic
staining or markedly stronger than normal breast acini. The percentage of the expression of
eEF1A2 was assigned by comparison with the positive internal controls. (see also Fig 1).
eEF1A2 showed some expression in normal breast parenchyma. eEF1A2 expression was lim-
ited to the luminal side of epithelial ductal and acinar cells and was typically weak (1+) (Fig 2).
Positivity in normal breast acini has been used to calibrate the assessment of positivity in
neighboring cancer cells. Two pathologists evaluated each sample in a blinded manner. In case
of discordance, the sample was revaluated or assigned to a third pathologist.
Statistical analysis
We summarized data by using mean ± standard deviation (SD) or median and range, as
appropriate, for continuous variables and absolute frequencies and percentages for categorical
variables.
A pilot study to evaluate the prognostic significance of eEF1A2 expression in TBNC tissues
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The eEF1A2 was studied by means of a semi-quantitative score but also as a dichotomous
variable.
The eEF1A2 immunohistochemistry semi-quantitative score was calculated using the fol-
lowing formula: 0 × (percentage of cells staining absent [0]) + 1 × (percentage of cells staining
weakly [1+]) + 2 × (percentage of cells staining moderately [2+]) + 3 × (percentage of cells
staining strongly [3+]). In the literature, this score is called H-score and is often adopted to
evaluate immunohistochemistry results of tumor samples [42,43].
Regarding dichotomization, different criteria were used. On the one side, we evaluated the
effect of the eEF1A2 using cut-point values based on quantiles of the H score distribution such
as, median and tertiles. On the other, we used two approaches less tied to data and not based
on the H score distribution. The first considered “negative”, patients whose sum of the per-
centages of not-stained-cells [0] and weakly-stained-cells [1+] was greater than the sum of the
percentages of moderately-stained-cells [2+] and strongly-stained-cells [3+]. The second con-
sidered “negative”, patients who had no expression of eEF1A2 (100% expression at 0 or 1+).
Inter-rater reliability of eEF1A2 measurements was assessed by different methods. When
eEF1A2 was evaluated by means of the semi-quantitative H score were used both, the intraclass
Fig 1. Immunohistochemical expression of eEF1A2 in breast cancer. a: absence of expression (0); b: weak expression (1+); c: moderate expression (2+); d:
strong expression (3+). 20x magnification.
https://doi.org/10.1371/journal.pone.0218030.g001
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correlation coefficient (ICC) and the Bland Altman plot [44]. The ICC estimate and the 95%
confidence intervals (CIs) were obtained using the “psych” R statistical package based on single
rater, absolute-agreement, 2-way random effect model (ICC [2,1]) with 2 raters [45]. Even if
any attempt to qualitatively define acceptable levels of reliability may be subject to criticism,
the following guidelines were considered as general guidance for data interpretation. In partic-
ular, ICC values less than 0.5 were considered indicative of poor reliability, values between 0.5
and 0.75 indicative of moderate reliability, values between 0.75 and 0.9 indicative of good reli-
ability, and values greater than 0.90 indicative of excellent reliability [45]. When eEF1A2 was
evaluated by means of binary variables, inter-rater reliability was assessed by the Cohen’s
Kappa coefficient. As mentioned previously, to aid in the interpretation of the kappa values,
the classification proposed by Landis and Koch’s [46], was used: values equal or less than 0.20
were considered indicative of poor agreement, between0.21 and 0.40 of fair agreement,
between 0.41 and 0.60 of moderate agreement, between 0.61–0.80 of good agreement, and
between 0.81–1.00 of almost perfect agreement. However, the Cohen’s Kappa is sensitive to
the unbalanced answers given by raters and to the overall prevalence of responses. For this rea-
son, additional statistics were computed such as, the expected proportion of agreement, the
proportion of positive agreement, the proportion of negative agreement, prevalence index
Fig 2. Expression of eEF1A2 in normal breast parenchyma. a: expression in acinar cells; b: expression in ductal cells; c: weak (1+) expression in normal
ductal cells used to calibrate staining intensity in cancer cells (2+). 20x magnification.
https://doi.org/10.1371/journal.pone.0218030.g002
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(PI), the bias index (BI) and the prevalence adjusted bias kappa (PABAK). If PI and BI are
equals to 0, means that there are almost no bias and prevalence effect on Cohen’s K. To com-
pute these quantities the epiR package (function epi.kappa) of software R was used.
The association between H-score and clinical-pathological factors (age, type of surgery,
pathologic tumor stage (pT), pathologic nodal stage (pN), grading (G), Ki67, p53, recurrences
and death) were evaluated through Mann-Whitney test or Kruskall Wallis test, as appropriate.
The median follow-up was computed for censored patients, excluding women with the
events of interest.
The study population was described with regards to the two time-to-event end-points (DFS
and BCSS) by means of rates. These were computed as the ratio between the number of events
and the sum of women-year at risk using STATA software and the “sptime” function. DFS and
BCSS curves were plotted using the Kaplan-Meier method.
The association of the clinical-pathological and molecular factors with the two time-to-
event end-points was analyzed separately using Cox proportional hazards regression. We
checked proportional hazards assumption graphically and by means of the Therneau and
Grambsch test [47]. The functional form of continuous or semi-continuous covariates such as,
H score, was assessed by means of Martingale residuals. Hazard ratios (HRs) and their 95%
CIs were reported. Statistically significant variables at 10% level at univariate analysis were
selected as candidate prognostic factors for multivariate Cox analysis. Moreover, to choose the
variables for the final multivariate model, it was important to consider the correlations among
them, their clinical relevance as well as the concept of parsimonious modelling, because of the
small number of events in this study. Since, in our study eEF1A2 had a large proportion of
observations with an H score equals to zero, an additional analysis was performed in presence
of a spike at zero (SAZ) covariate, according to the method proposed by Royston and Lorenz,
[48–50]. Their method, called “FP-spike”, models the continuous non-zero observations of the
SAZ covariate parametrically, using the fractional polynomials (FP), and adds to the Cox
model a binary indicator variable (v), taking value equals to one when the SAZ covariate equals
zero, and zero otherwise. The method consists of two stages: the first aims to identify the best
FP function when also v is included in the model; the second to assess if v or the FP component
can be eliminated without worsening the model fit. This second stage aims to understand if a
sort of “dose-response” effect is present in the data and it is performed with the likelihood
ratio test. As usual in Cox models, this method allows to consider the effect of other covariates
into the model. Statistical analyses were conducted with R version 3.0.3 and STATA 14.2 (Sta-
taCorp, College Station, TX). All p-values (p) were two-tailed and, when not stated differently,
differences were considered statistically significant when p< 0.05.
Results
Patient characteristics
The study enrolled a cohort of 250 TNBC women who received diagnosis of primary cancer
from 2002 to 2011 and underwent to surgical treatment in ASUITS. We excluded 166 women
(66.4%) for the following reasons: 21 received neoadjuvant treatment, 11 had distant metasta-
ses at diagnosis, 30 had personal history of breast cancer, 52 were no chemotherapy treated, 33
had no follow-up information and finally for 19 cases the tumor tissue was insufficient for the
immunohistochemistry evaluation. Then, 84 women were eligible for the analysis (see Fig 3).
The average age was 61 years old (range, 28–78 years), and advanced cancer (stage II or higher)
was present in 44 patients (52.38%). 65 patients (77.38%) underwent conservative surgery
while 19 patients (22.62%) mastectomy (Table 1). These 19 women were candidate for mastec-
tomy accordingly to current indications [51]; these types of cancer cannot be treated with
A pilot study to evaluate the prognostic significance of eEF1A2 expression in TBNC tissues
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conservative surgery for the following reasons: large tumor to breast size ratio (7), multicentric
lesions (6), suspected genetic susceptibility subsequently proven (2), advanced (pT4) breast
cancer (2), retroareolar carcinoma (1) and patient preference (1).
Although ductal carcinoma NOS was the most frequent TNBC histologic subtype, a mean-
ingful number of cases exhibited apocrine and medullary like features (9.52% and 5.95%
respectively). The majority of the patients in our cohort had high Modified Bloom Richardson
(MBR) pathologic grade (82.05%) and a significantly higher proportion of cases (82.14%) that
were under high risk Ki67 category (> = 20%) as defined by St. Gallen international expert
consensus recommendations. The median H-score value was 10 (range: 0–260), and tertiles
respectively 0 and 56.69 (see Fig 4). Only 6 (7.23%) and 16 (19.28%) patients resulted eEF1A2
positive according to the dichotomization criteria reported in the statistical analysis section.
High AR expression (�10%) was found in 32.10% TNBC. A large percentage of patients
(64.29%) had negative lymph nodes whereas 35.71% patients had metastatic lymph nodes. Dis-
section of the axillary lymph nodes was necessary in 37 patients (44.05%). All patients under-
went post-operative adjuvant chemotherapy according to inclusion criteria.
During the follow-up period after surgery, relapse occurred in 31 patients (36.90%): 9 devel-
oped loco-regional recurrences and 21 distant metastases. The most common site of the first
Fig 3. Flow-chart of the patient cohort included in this study.
https://doi.org/10.1371/journal.pone.0218030.g003
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Table 1. Patients characteristics (n = 84).
Characteristics n %
Age (years)
Median (min-max) 59 (28–78)
Type of Surgery
Conservative 65 77.38
Mastectomy 19 22.62
Lymph nodal Surgery
Axillary Dissection 37 44.05
No Axillary Dissection 47 55.95
Tumor Size
T1(<2 cm) 50 59.52
T2 (2–5 cm) 32 38.10
T3-4 (>5 cm) 2 2.38
Invasive Cancers Histology Subtype
Ductal 48 57.14
Solide 17 20.24
Other (Medullary-Lobular-
Apocrine)
19 22.62
Lymph Node Metastasis
N0 54 64.29
N1mi 4 4.76
N+ 26 30.95
Stage
I 40 47.62
II 33 39.29
III 11 13.09
Gradea
G1 1 1.28
G2 13 16.67
G3 64 82.05
Ki67
<20% 15 17.86
> = 20% 69 82.14
eEF1A2 (H-score)
Median (min-max) 10 (0–260)
eEF1A2b
Negative 77 92.77
Positive 6 7.23
eEF1A2c
Negative 67 80.72
Positive 16 19.28
ARa
Negative (<10%) 55 67.90
Positive (> = 10%) 26 32.10
p53
Negative 28 33.33
Positive 56 66.67
Family History of Breast Cancera
No 49 62.03
(Continued)
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Table 1. (Continued)
Characteristics n %
First-degree relative 19 24.05
Second-degree relative 11 13.92
Radiotherapya
Yes 62 78.48
No 17 21.52
Adjuvant Chemotherapy
Yes 84 100.00
No 0 0.00
aNumbers does not add up to the total due to missing values
b Patient is considered eEF1A2 negative if the sum of the percentage of cells staining absent [0] and of the percentage
of cells staining weakly [1+] is greater than the sum of the percentage of cells staining moderately [2+] and strongly
[3+].
c Patient was considered eEF1A2 negative if it had no expression of eEF1A2 (100% expression at 0 or 1+), and
positive otherwise.
https://doi.org/10.1371/journal.pone.0218030.t001
Fig 4. Box plots of eEF1A2 values according to presence (in the left) or exclusion (in the right) of 0 values.
https://doi.org/10.1371/journal.pone.0218030.g004
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distant recurrence was the lung (47.62%, 10 out of 21 women with metastases). In 5 women, a
contralateral breast cancer was diagnosed: 2 TNBC, 2 Luminal B Her 2 negative and 1 in situ
breast cancer. Two patients had a second primary invasive cancer: an ovarian cancer and one
choroid melanoma. 21 women died (25.00%) 18 of whom for breast cancer (after a disease
relapse) and 3 for other causes.
Analysis of eEF1A2 expression: Inter-rater reliability between two raters
Two pathologists independently assigned to each sample an immunohistochemical score in a
blinded manner. A third senior pathologist revaluated the discrepant cases and discordance
was adjudicated by consensus.
We conducted an inter-rater reliability analysis to evaluate consistency of eEF1A2 readings
for H score by computing ICC and through Bland-Altman analysis (plot and statistics). The
obtained ICC value was 0.72 (indicating moderate reliability) and its 95% confidence interval
ranged between 0.60–0.80 (S1 Table). Scatter plot of measures of two raters and Bland-Altman
Plot are shown in Supplementary material (S1 and S2 Figs): from Bland Altman plot we
observed that most of measurements respected the Limit of Agreements and the points were
scattered all over the place, above and below zero. Then it suggested that there was no consis-
tent bias of one reading versus the other. Indeed, the value of mean bias of H-score was close
to zero (0.94); it meant that on average, the second rater measured only 0.94 units more than
the first one. (all Bland-Altman statistics are reported in S2 Table). We evaluated inter-rater
reliability also for the two binary eEF1A2 variables: K statistics were respectively 0.64 and 0.52
(substantial agreement and moderate agreement). Since this statistic may be affected by bias
and prevalence, S3 Table shows other useful statistics: for both binary variables, bias and preva-
lence were present, so the unadjusted kappa could not be considered a reliable indicator of
measurements agreement and the PABAK should be preferred. This was equals to 0.88, sub-
stantial agreement, and 0.61, moderate agreement, respectively.
Association between eEF1A2 expression and clinical-pathological
parameters
Table 2 and S4 Table illustrate the association between eEF1A2 expression levels and clinical-
pathological features, considered as a semi-continuous score or as a binary variable, respec-
tively. eEF1A2 expression was higher in older women (p = 0.03) and associated with AR posi-
tive expression (p = 0.002). We did not observe other statistically significant association at 5%
level.
Analysis of DFS and BCSS with respect to standard prognostic factors
Median follow-up time was 9.05 years (5.55–15.35). Median DFS and BCSS were not reached:
5-year DFS and BCSS were 72.6%, 95% CI: 63.7%-82.8%; and 83.2%, 95% CI: 75.5%-91.6%,
respectively. As shown in Table 3, conventional prognostic factors, including clinical tumor
size, nodal status and disease stage were found to have a statistically significant association
with DFS at univariate analysis (HR = 2.32, 95% CI: 1.14–4.71; HR = 2.64, 95% CI: 1.30–5.37;
and HR = 8.90, 95% CI: 3.47–22.85, respectively). No statistically significant differences in
DFS were observable between women with conservative surgery or mastectomy. Patient’s age
was not associated with DFS too. We found similar results for BCSS, as illustrated in Table 4.
Tumor size, node status and overall stage was found to be associated with an increased hazard
of BCSS (hazard ratio respectively: HR = 3.72, 95% CI: 1.39–9.97; HR = 4.57, 95% CI: 1.70–
12.24; and HR = 16.67, 95% CI: 4.81–57.72). Additionally, women aged over 60 years old, with
A pilot study to evaluate the prognostic significance of eEF1A2 expression in TBNC tissues
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mastectomy and axillary dissection, had poor prognosis (hazard ratio respectively: HR = 3.27,
95% CI: 1.07–9.95; HR = 3.16, 95% CI: 1.24–8.01; and HR = 2.57, 95% CI: 0.96–6.89).
Analysis of DFS and BCSS with respect to eEF1A2 expression
At univariate analysis increasing values of eEF1A2 expression were associated with a worse
prognosis even if results did not reach statistical significance at 5% level (HR = 1.04, 95% CI:
Table 2. H score values in relation to baseline characteristics.
N (%) H-Score
Variable Median
(min-max)
p-value
Age (Years)
<60 0 (0–210) 0.03
> = 60 17.50 (0–260)
Type of Surgery
Conservative 10 (0–260) 0.68
Mastectomy 5 (0–200)
Lymph nodal Surgery
Axillary Dissection 10 (0–205) 0.27
No Axillary Dissection 5 (0–260)
Tumor Size
T1(<2 cm) 5 (0–205) 0.82
T2 (2–5 cm) 10 (0–260)
Lymph Node Metastasis
N0 2.50 (0–205) 0.09
N+ 15.00 (0–260)
Stage
I 7.50 (0–205) 0.76
II 7.50 (0–260)
III 10 (0–210)
Gradea
G1-G2 50.30 (0–190) 0.30
G3 3.50 (0–260)
Ki67
<20% 80 (0–190)
> = 20% 5 (0–260) 0.15
p53
Negative 5 (0–210) 0.69
Positive 10 (0–260)
ARa
Negative (<10%) 0 (0–210) 0.002
Positive (> = 10%) 90 (0–260)
Family History of Breast Cancera
No 5 (0–260) 0.63
First/Second -degree relative 10 (0–210)
Radiotherapya
Yes 10 (0–260) 0.31
No 2 (0–140)
aNumbers does not add up to the total due to missing values
https://doi.org/10.1371/journal.pone.0218030.t002
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Table 3. Results from univariate Cox models for DFS.
Characteristics E Women-years Rates (x100) HR (95% CI) P-value
Age (Years)
<60 9 167.51 5.37 (2.80–10.33) 1.00 (Reference) 0.44
> = 60 14 189.86 7.37 (4.38–12.45) 1.32 (0.64–2.71)
Type of Surgery
Conservative 15 290.55 5.16 (3.11–8.56) 1.00 (Reference) 0.20
Mastectomy 8 66.82 11.97 (5.99–23.94) 1.67 (0.76–3.63)
Lymph nodal Surgery
No Axillary Dissection 13 140.65 9.24 (5.37–15.92) 1.00 (Reference) 0.06
Axillary Dissection 10 216.72 4.61 (2.48–8.58) 1.97 (0.96–4.04)
Tumor Size
T1(<2 cm) 9 231.23 3.89 (2.03–7.48) 1.00 (Reference) 0.02
T2-3-4 (> = 2cm) 14 126.14 11.10 (6.57–18.74) 2.32 (1.14–4.71)
Lymph Node Metastasis
N0 10 249.26 4.01 (2.16–7.46) 1.00 (Reference) 0.008
N1mi-N1 13 108.11 12.02 (6.98–20.71) 2.64 (1.30–5.37)
Stage
I 6 188.37 3.19 (1.43–7.09) 1.00 (Reference)
I 9 144.02 6.25 (3.25–12.01) 1.57 (0.67–3.64) 0.30
III 8 24.98 32.02 (16.01–64.03) 8.90 (3.47–22.85) <0.001
Grade
G1-G2 0 70.00 0 1.00 (Reference) 0.12
G3 22 260.88 8.43 (5.55–12.81) 2.32 (0.70–7.66)
Ki67
<20% 2 71.40 2.80 (0.70–11.20) 1.00 (Reference) 0.89
> = 20% 21 285.97 7.34 (4.79–11.26) 0.94 (0.38–2.30)
p53
Negative 7 119.10 5.88 (2.80–12.33) 1.00 (Reference) 0.28
Positive 16 238.27 6.72 (4.11–10.96) 1.60 (0.69–3.73)
AR
Negative (<10%) 13 234.84 5.54 (3.21–9.53) 1.00 (Reference) 0.18
Positive (> = 10%) 9 108.54 8.29 (4.31–15.94) 1.67 (0.79–3.53)
H scorea 1.04 (0.99–1.10) 0.11
eEF1A2b
Negative 20 331.53 6.03 (3.89–9.35) 1.00 (Reference) 0.07
Positive 3 20.83 14.40 (4.64–44.64) 2.64 (0.91–7.61)
eEF1A2c
Negative 17 287.91 5.90 (3.67-9-50) 1.00 (Reference)
Positive 6 64.46 9.31 (4.18–20.71) 1.53 (0.65–3.60) 0.33
Family History of Breast Cancer
No 12 209.62 5.72 (3.25–10.08) 1.00 (Reference)
First-degree relative 5 76.54 6.53 (2.72–15.70) 1.09 (0.45–2.63) 0.85
Second-degree relative 5 50.37 9.93 (4.13–23.85) 1.35 (0.50–3.68) 0.55
Radiotherapy
No 13 277.43 4.69 (2.72–8.07) 1.00 (Reference) 0.16
(Continued)
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0.99–1.10, p = 0.11 for DFS and HR = 1.05, 95% CI: 0.99–1.12, p = 0.08 for BCSS), Tables 3
and 4. Considering the two dichotomous variables, results were in the same direction even if
characterized by less precise estimates, Tables 3 and 4. Fig 5 shows the Kaplan-Meier curves
for DFS and BCSS for the two dichotomous variables, respectively. The eEFIA2 H score
dichotomized using the median value was not associated either with DFS or BCSS (p = 0.74
and p = 0.71 respectively). Analogous results were observed using tertiles as cut-off values for
the H score, even if patients in the third tertile compared to those in the first one (with score
value of zero), showed an increased hazard for the events of interest (p = 0.50 and p = 0.19
respectively).
Regarding DFS, adjusted for disease stage, higher values of the score were associated with a
worst DFS (HR = 1.05, 95% CI: 1.007–1.105, p = 0.04), Table 5 –Model 1. Type of surgery,
tumor size and lymph node status were correlated with tumor stage, but only the latter was
evaluated for inclusion in the multivariable analysis. When dichotomous versions of eEF1A2
were considered, similar results were obtained. Compared to women with a dominance of
cells with absent or weakly staining, women with more than 50%, of moderately or strongly
stained cells as, had an HR = 2.61, 95% CI: 0.88–7.71, p = 0.08 (Table 5 –Model 2). Similar
effects were observed also when a less strict definition of “positivity” was considered,
HR = 1.80, CI: 0.75–4.33, p = 0.19, respectively (Table 5 –Model 3).
Regarding BCCS, disease stage and eEF1A2 expressed by the H score, showed again inde-
pendent prognostic roles, Table 6 –Model 1. Higher values of the score were associated with
worst prognosis (HR = 1.07, 95% CI: 1.01–1.14, P-value = 0.026). Similar results were observed
for the two dichotomous variables (HR = 4.25, 95% CI: 1.16–15.54, P-value = 0.029 and
HR = 2.95, CI: 1.07–8.09, p = 0.036, respectively), Table 6 –Models 2 and 3.
For DFS, a simple linear function (FP1) to model the relationship between the non-zero values
of the H score and the hazard was selected by the FP-spike procedure, Table 7. Moreover, when
the indicator variable, v, and FP1 component were tested for removal, both resulted important for
the model fit (P-values = 0.032 and P-value = 0.006, respectively). As already shown, adjusting for
stage, we observed that increasing values of eEF1A2 were associated with poor prognosis. The FP
spike model showed that also women with an H score of zero, have a risk of a recurrence higher
compared to women with values different from zero (P-value = 0.039). For BCSS, by the FP-spike
analysis (Table 7), the addition of the binary component did not bring any substantial contribu-
tion to the model fit. In particular, the best functional relationship between eEF1A2 and the haz-
ard of was described by a linear model confirming that an increase of H-score values was
associated with an increase in worse prognosis.
Discussion
TNBC is a heterogeneous disease, highly variable with respect to its biology and etiology and
more likely to be poorly differentiated; these cancers often display an aggressive clinical course
Table 3. (Continued)
Characteristics E Women-years Rates (x100) HR (95% CI) P-value
Yes 5 69.40 7.20 (3.00–17.31) 0.54 (0.24–1.27)
E = number of DFS events.
a Results are reported as 5-unit increase.
b Patient is considered eEF1A2 negative if the sum of the percentage of cells staining absent [0] and of the percentage of cells staining weakly [1+] is greater than the sum
of the percentage of cells staining moderately [2+] and strongly [3+].
c Patient was considered eEF1A2 negative if it had no expression of eEF1A2 (100% expression at 0 or 1+), and positive otherwise.
https://doi.org/10.1371/journal.pone.0218030.t003
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Table 4. Results from univariate Cox models for BCSS.
E Women-years Rates (x100) HR (95% CI) P-value
Age (Years)
<60 4 182.19 2.20 (0.82–5.85) 1.00 (Reference)
> = 60 10 205.57 4.38 (2.28–8.41) 3.27 (1.07–9.95) 0.04
Type of Surgery
Conservative 7 306.60 1.96 (0.88–4.36) 1.00 (Reference)
Mastectomy 7 81.17 8.62 (4.11–18.09) 3.16 (1.24–8.01) 0.02
Lymph nodal Surgery
No Axillary Dissection 10 162.79 6.14 (3.31–11.42) 1.00 (Reference)
Axillary Dissection 4 224.98 1.33 (0.43–4.13) 2.57 (0.96–6.89) 0.06
Tumor Size
T1(<2 cm) 3 239.91 1.25 (0.40–3.88) 1.00 (Reference)
T2-3-4 (> = 2cm) 11 146.76 7.49 (4.15–13.53) 3.72 (1.39–9.97) 0.009
Lymph Node Metastasis
N0 4 258.47 1.55 (0.58–4.12) 1.00 (Reference)
N1mi-N1 10 128.21 7.80 (4.20–14.50) 4.57 (1.70–12.24) 0.003
Stage
I 2 194.14 0.52 (0.07–3.66) 1.00 (Reference)
II 5 157.95 3.17 (1.32–7.61) 1.94 (0.55–6.90) 0.3
III 7 35.67 19.63 (9.36–41.17) 16.67 (4.81–57.72) <0.001
Grade
G1-G2 0 70.00 0 1.00 (Reference)
G3 14 288.90 4.85 (2.87–8.18) -
Ki67
<20% 1 74.32 1.35 (0.19–9.55) 1.00 (Reference)
> = 20% 13 313.44 3.83 (2.17–6.74) 1.19 (0.34–4.10) 0.79
p53
Negative 4 128.97 3.10 (1.16–8.26) 1.00 (Reference)
Positive 10 258.80 3.48 (1.81–6.68) 1.52 (0.60–4.66) 0.46
AR
Negative (<10%) 10 253.31 3.95 (2.12–7.34) 1.00 (Reference)
Positive (> = 10%) 4 118.37 3.38 (1.27–9.00) 0.88 (0.31–2.51) 0.82
H scorea 1.05 (0.99–1.12) 0.08
eEF1A2b
Negative 12 358.88 3.34 (2.00–5.89) 1.00 (Reference) 0.06
Positive 2 22.80 8.77 (2.19–35.08) 3.18 (0.92–10.99)
eEF1A2c
Negative 10 312.80 3.20 (1.72–5.94) 1.00 (Reference)
Positive 4 68.88 5.81 (2.18–15.47) 2.48 (0.92–6.63) 0.07
Family History of Breast Cancer
No 8 226.05 3.54 (1.77–7.08) 1.00 (Reference)
First-degree relative 3 85.88 3.49 (1.13–10.83) 0.74 (0.20–2.71) 0.65
Second-degree relative 2 54.74 1.83 (0.26–12.97) 1.61 (0.50–5.14) 0.42
Radiotherapy
No 6 294.18 2.04 (0.92–4.54) 1.00 (Reference)
(Continued)
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[52]. Moreover, due to the lack of specific cellular receptors in cancer cells, targeted therapies
have not been established, and, as a result, TNBC mortality remains high [11,52]. Many studies
documented a high rate of recurrence among TNBC patients [53,54]. In our TNBC cohort we
found a distant recurrence rate of 36.90%, in agreement with literature data [53]. The risk of
Table 4. (Continued)
E Women-years Rates (x100) HR (95% CI) P-value
Yes 4 79.69 5.02 (1.88–13.37) 0.44 (0.14–1.34) 0.15
E = number of BCSS events.
a Results are reported as 5-unit increase.
b Patient is considered eEF1A2 negative if the sum of the percentage of cells staining absent [0] and of the percentage of cells staining weakly [1+] is greater than the sum
of the percentage of cells staining moderately [2+] and strongly [3+].
c Patient was considered eEF1A2 negative if it had no expression of eEF1A2 (100% expression at 0 or 1+), and positive otherwise
https://doi.org/10.1371/journal.pone.0218030.t004
Fig 5. Estimated disease-free survival (A-C) and breast cancer specific survival (B-D) according to eEF1A2 dichotomizations. In panels A and B, a patient
is considered eEF1A2 negative if the sum of the percentage of cells staining absent [0] and of the percentage of cells staining weakly [1+] is greater than the sum
of the percentage of cells staining moderately [2+] and strongly [3+]; in panels C and D, a patient was considered eEF1A2 negative if it had no expression of
eEF1A2 (100% expression at 0 or 1+), and positive otherwise.
https://doi.org/10.1371/journal.pone.0218030.g005
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distant recurrences appeared to be high in the first 1–4 years after diagnosis and treatment
[54,55]: our findings confirmed this, as more than 70% of the recurrences occurred within 4
years, with a peak during the 1 year. In our TNBC cohort, on univariate analysis, tumor size,
nodal status and stage were associated with DFS and BCSS, in agreement with a recent study
[56,57]. Moreover, we found that women with a conservative surgery exhibited an improved
BCSS in comparison to patients treated with mastectomy (univariate analysis) as recently
shown by other authors [14,57].
The eEF1A2 protein delivers aminoacyl tRNAs to the ribosome and it is selectively
expressed in specialized tissues such as heart, skeletal muscles and brain [58]. Several studies
demonstrated that eEF1A2 acts as a growth-enhancing protein in many human cancers. Its
ectopic expression has been shown to favor oncogenesis by stimulating the phospholipid sig-
naling pathway and the Akt-dependent cell migration [59].
There is also evidence that eEF1A2 overexpression is predictive of patient’s prognosis in
various epithelial cancers, which are sometimes positive and sometimes negative [38,40,60,61].
Recently, other studies have reported that the upregulation of eEF1A2 predicted a prolonged
survival in ovarian [62] and in HER2 negative breast cancer [38]. The difference in prognostic
Table 5. Results from multivariate Cox models for DFS.
Model 1 Model 2 Model 3
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
H scorea 1.05 (1.007–1.105) 0.04 eEF1A2b eEF1A2c
Negative 1.00 (Reference) Negative 1.00 (Reference)
Positive 2.61 (0.89–7.71) 0.08 Positive 1.80 (0.75–4.33) 0.19
Stage Stage Stage
I 1.00 (Reference) I 1.00 (Reference) I 1.00 (Reference)
II 1.41 (0.59–3.33) 0.44 II 1.46 (0.62–3.47) 0.37 II 1.42 (0.60–3.36) 0.43
III 9.80 (3.74–25.12) <0.001 III 8.86 (3.40–23.03) <0.001 III 9.34 (3.58–24.35) <0.001
a Results are reported as 5-unit increase.
b Patient is considered eEF1A2 negative if the sum of the percentage of cells staining absent [0] and of the percentage of cells staining weakly [1+] is greater than the sum
of the percentage of cells staining moderately [2+] and strongly [3+].
c Patient was considered eEF1A2 negative if it had no expression of eEF1A2 (100% expression at 0 or 1+), and positive otherwise
https://doi.org/10.1371/journal.pone.0218030.t005
Table 6. Results from multivariate Cox models for BCSS.
Model 1 Model 2 Model 3
HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
H scorea 1.07 (1.008–1.140) 0.026 eEF1A2b eEF1A2c
Negative 1.00 (Reference) Negative 1.00 (Reference)
Positive 4.25 (1.16–15.55) 0.029 Positive 2.95 (1.07–8.09) 0.036
Stage Stage Stage
I 1.00 (Reference) I 1.00 (Reference) I 1.00 (Reference)
II 1.80 (0.51–6.43) 0.36 II 1.91 (0.54–6.77) 0.23 II 1.83 (0.51–6.51) 0.32
III 17.44 (5.02–60.63) <0.001 III 16.57 (4.78–57.40) <0.001 III 16.13 (4.70–55.37) <0.001
a Results are reported as 5-unit increase.
b Patient is considered eEF1A2 negative if the sum of the percentage of cells staining absent [0] and of the percentage of cells staining weakly [1+] is greater than the sum
of the percentage of cells staining moderately [2+] and strongly [3+].
c Patient was considered eEF1A2 negative if it had no expression of eEF1A2 (100% expression at 0 or 1+), and positive otherwise.
https://doi.org/10.1371/journal.pone.0218030.t006
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significance of eEF1A2 overexpression might be due to the different mechanisms that are
implicated in and on the pathways that are altered in tumors [63]. Two studies reported that
the overexpression of eEF1A2 in tumors did not completely depend on the genomic status of
this locus, suggesting instead that it depends on an increase of the transcription and/or on
mRNA stability [29,34]. The regulatory mechanisms of eEF1A2 overexpression in tumors is
complex and it can involve miRNA too [64].
In this study, we determined eEF1A2 protein expression levels by IHC in TNBC tissue and
assessed its prognostic role with respect to DFS and BCSS. To our knowledge, this is the first
study investigating eEF1A2 protein expression in tissue samples of TNBC. Different statistical
approaches were considered to evaluate the association with clinical outcomes. Firstly, we
summarized eEF1A2 expression by means of the semi-quantitative H score and, after the
adjustment for tumor stage, a statistically significant association between increasing values of
the biomarker and the increase of hazards for adverse events was observed (recurrence-DFS or
death-BCSS). Similar results were obtained for BCSS with other statistical methods (FP-spike
model) taking the high proportion of zeros in the H score into account [48–50]. However, for
DFS the FP-spike model gave a statistically significant adverse effect in women with an H
score of zero compared to those with a positive one. The interpretation of this observation
deserves further investigations, maybe by evaluating eEF1A1 isoform levels. In fact, it has been
demonstrated a reciprocal influence of the two proteins at expression levels in many cancers
and the possibility that the overexpression of eEF1A1 protein sustains cancer progression
[40,65]. The use of categorical variables based on quantiles of the H score distribution (median
and tertiles) was marginally treated in this paper due to the limits of the H score itself and to
the main data dependence on such measures.
Differently from our evidence, another study found that the overexpression of eEF1A2 pro-
tein was a predictor of good prognosis in breast cancer [38]. In this regard, eEF1A2 expression
in other tumor entities showed differing results: some studies attributed a higher expression of
eEF1A2 with a poor prognosis (pancreatic ductal adenocarcinoma [60] and localized prostate
cancer [66]), while others found that it was associated with a favorable outcome (non-small
cell lung cancer [67] and breast cancer [38]). It is worth to underline that with respect to 80%
of pancreatic cancers, only 30%-60% of breast cancer showed overexpression of eEF1A2 [38],
Table 7. Results from multivariate Cox models for DFS and BCSS using the FP-Spike approach for eEF1A2.
DFS BCSS
log HR (95% CI) P-value log HR (95% CI) P-value
First stagea
v 1.07 (0.05–2.09) 0.039 0.41 (-0.87–1.68) 0.53
FP1: Linear 0.009 (0.003–0.156) 0.003 0.008 (0.0007–0.0162) 0.032
Stage
I (reference) (reference)
II 0.40 (-0.47–1.27) 0.364 0.60 (-0.67–1.88) 0.353
III 2.44 (1.45–3.42) <0.001 2.86 (1.62–4.10) <0.001
Second stageb
FP1 (dropping v) 0.032 0.531
v (dropping FP1) 0.006 0.040
Log HR, logarithm of the hazard ratio; FP1, first degree fractional polynomial.
a In the first stage of PF-spike procedure, the full model including both the indicator v, eEF1A2 and other covariates is fitted. The selected model is taken then taken to
the second stage.
b In the second stage both v and eEF1A2 are tested for removal.
https://doi.org/10.1371/journal.pone.0218030.t007
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underlying the heterogeneity of eEF1A2 expression in breast cancers. Our evidence suggests
that in TNBC high levels of eEF1A2 protein sustain cancer aggressiveness. Moreover, most of
the studies analyzing eEF1A2 [33,38,66], quantified mRNA expression whereas in our study
we measured protein levels that might give different results [65]. An explanation may reside in
the fact that mRNA quantity is often not quantitatively equivalent to protein levels. In particu-
lar, the half-lives of eEF1A2 protein is of about 95 hours, whereas the half-lives of the mRNAs
are shorter (about 60 hours) [68]. It is conceivable that high levels of eEF1A2 protein led to a
worse prognosis in TNBC by sustaining cell survival, migration and invasion, by the ability of
the protein to upregulate MMP-9, to activate PKR and to suppress PI3K/Akt/NF-kB signaling
pathway [61, 69,70].
Notably, in our TNBC cohort, eEF1A2 expression was higher in older women (p = 0.03)
and was associated with AR positive expression (p = 0.002). We did not observe any statisti-
cally significant association between eEF1A2 expression and type of surgery, tumor size or
stage, Ki-67, p53, grading and family history of breast cancer in accordance with a large cohort
study of 438 primary breast cancer specimen [38]. We obtained similar results considering a
different definition of DFS that is, excluding contralateral breast cancers and second primary
invasive cancers (S5 Table).
Further studies using a larger independent data set of TNBCs are necessary to confirm the
prognostic value of eEF1A2 protein before an implementation in clinical practice. Certainly,
the measurement of protein level is very interesting because immunohistochemistry is the
main technique available in most pathology labs to evaluate a marker. It is worth noting that
from inter-rater reliability analysis, considering the calculated measures of reliability, H-score
resulted reproducible (ICC = 0.72 95% CI = 0.60–0.80), also by using the two categorized
scores (PABAK = 0.61 and 0.88). In our cohort, we are aware of the fact that the use of the H
score and of categorical variables derives from its distribution, it may assign sometimes the
same score or the same class to women with quite different patterns, making the interpretation
difficult. This is a limit of IHC due to the heterogeneity of the tumors among the tissues (i.e.
different percentage of positive cells and different cell staining intensity). The evaluation of
mRNA expression levels in formalin-fixed, paraffin-embedded tissue could contribute to clar-
ify the potency of eEF1A2 as prognostic biomarker in TNBC, as well as to assign a score in
doubt cases. In this respect, it is outstanding the agreement of our evidence on eEF1A2 protein
levels with the annotation of eEF1A2 mRNA expression levels in TNBC in Kaplan Meier Plot-
ter [71]. In particular, we chose gene expression array database obtained from JetSet best
probe set analysis to assure an unbiased quality score for probe set, and from patients with sys-
temic treatments. In those patients with high expression levels of eEF1A2 mRNA a shorter
DFS was recorded (25 months) with respect to the DFS of the low expression cohort (47.51
months) with a p value = 0.024; HR = 1.64 (1.06–2.54).
Conclusion
In conclusion, our data showed that high expression levels of eEF1A2 protein in formalin-
fixed paraffin-embedded TNBC tissues is associated with worse prognosis. These results
encourage extending the study on eEF1A2 expression levels in a larger independent cohort of
TNBC to evaluate its prognostic usefulness for the clinical practice and possibly as potential
target for the therapy.
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